Avid Bioservices, Inc. (CDMO) Research

Avid Bioservices, Inc. operates as a Contract Development and Manufacturing Organization (CDMO), specializing in the development and CGMP-compliant production of biopharmaceutical drug substances. Their core expertise lies in compounds derived from mammalian cell culture, providing both clinical and commercial scale manufacturing solutions. The company is proficient in producing critical therapeutics such as monoclonal antibodies and recombinant proteins. Beyond manufacturing, their comprehensive service portfolio encompasses CGMP manufacturing for drug substances, bulk packaging, rigorous release and stability testing, and essential regulatory submission and support. Additionally, Avid Bioservices offers a range of process development services, including the optimization of upstream and downstream processes, alongside the development, testing, and characterization of analytical methods. Avid Bioservices primarily serves clients within the biotechnology and biopharmaceutical industries. The company, which was originally incorporated in 1981, was known as Peregrine Pharmaceuticals, Inc. before officially rebranding to Avid Bioservices, Inc. in January 2018. Its corporate headquarters are situated in Tustin, California.

Market snapshot

Symbol
CDMO
Price
$12.49
Day change
0.00%
Market cap
$798.9M
P/E ratio
-5.61x
52-week range
5.9-12.51
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$8.00

Peer companies

  • Albireo Pharma, Inc. (ALBO)
  • ASLAN Pharmaceuticals Limited (ASLN)
  • Chimerix, Inc. (CMRX)
  • Exscientia plc (EXAI)
  • Harpoon Therapeutics, Inc. (HARP)
  • Intercept Pharmaceuticals, Inc. (ICPT)
  • Icosavax, Inc. (ICVX)
  • Ikena Oncology, Inc. (IKNA)

Recent insider activity

  • Ziebell Mark R — D-Return (14286 shares) on 2025-02-05
  • Ziebell Mark R — D-Return (21429 shares) on 2025-02-05
  • Ziebell Mark R — D-Return (1733 shares) on 2025-02-05
  • Ziebell Mark R — D-Return (98120 shares) on 2025-02-05
  • Ziebell Mark R — D-Return (17679 shares) on 2025-02-05

Open Avid Bioservices, Inc. (CDMO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.